# Masofaniten

Source: https://onco.cc/drugs/masofaniten/  
OnCo record `masofaniten` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A drug designed to block the part of the androgen receptor that resistant variants keep; its phase 2 was stopped for futility and development ended.

## Summary

ESSA Pharma terminated the phase 2 of masofaniten + enzalutamide in mCRPC (2024) after a futility analysis on PSA90; the company later discontinued development (2025). The EXTRA-PC investigator trial in mHSPC closed early. AR-NTD inhibition remains unproven clinically despite compelling biology (AR-V7).

## Fields

- Kind: Treatment
- Status: withdrawn
- Last checked: 2026-09-06
- Tags: failed-so-far
- Code: EPI-7386
- Modality: Small-molecule AR N-terminal domain inhibitor
- Mechanism: Binds the disordered N-terminal domain of AR, intended to inhibit full-length and splice-variant AR.

## Sources

- ESSA terminates phase 2 (OncLive): https://www.onclive.com/view/essa-discontinues-phase-2-study-of-masofaniten-plus-enzalutamide-in-mcrpc

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- targets: [Androgen receptor](https://onco.cc/targets/androgen-receptor/)
- companies: [ESSA Pharma](https://onco.cc/companies/essa-pharma/)
- terms: [AR-V7 splice variant](https://onco.cc/terms/ar-v7/)
- trials: [Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer](https://onco.cc/trials/nct06312670/)

---
JSON: https://onco.cc/api/v1/entities/masofaniten.json